micafungin has been researched along with fosfluconazole* in 3 studies
1 review(s) available for micafungin and fosfluconazole
| Article | Year |
|---|---|
[Clinical efficacies of antifungal injections].
The incidence of fungal infection is increasing. Amphotericin B has been the gold standard in antifungal chemotherapy for a long time. Within the past few years, three novel antifungal agents have been approved to evaluate the clinical benefits in Japan. Liposomal amphotericin B is developed to reduce toxicities of amphotericin B. Voriconazole, a kind of the new broad-spectrum triazoles, is recommended for the primary treatment of invasive aspergillosis. Micafungin is a new lipopeptide antifungal agent of the echinocandin class. These drugs might provide an individualized and more effective antifungal therapy for each patient. On the other hand, we need to establish a new standard therapy. Topics: Amphotericin B; Antifungal Agents; Drug Delivery Systems; Echinocandins; Fluconazole; Humans; Infusions, Intravenous; Injections; Itraconazole; Lipopeptides; Liposomes; Micafungin; Mycoses; Organophosphates; Pyrimidines; Triazoles; Voriconazole | 2008 |
1 trial(s) available for micafungin and fosfluconazole
| Article | Year |
|---|---|
[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation].
Invasive fungal infection (IFI) is a serious complication of chemotherapy for hematological malignancies and autologous/allogeneic hematopoietic stem cell transplantation in children and shows a high mortality rate. We performed a randomized trial comparing micafungin (MCFG), a new anti-fungal agent, with fosfluconazole, a prodrug of fluconazole (FF) conventionally used as a prophylactic agent, for prophylaxis against IFI. Cefpirome was administered as prophylaxis against bacterial infection, and meropenem+minocycline as an empiric window therapy for febrile neutropenia. MCFG 2 mg/kg/day (max 100 mg/day) and FF 10 mg/kg/day (max 400 mg/day) were both safe and effective (event free ratio of IFI, MCFG 94.4% vs FF 94.3%) without significant difference. Thus, MCFG is safe and can be used for prophylaxis against IFI in children. Topics: Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Echinocandins; Female; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lipopeptides; Male; Meropenem; Micafungin; Minocycline; Mycoses; Neutropenia; Opportunistic Infections; Organophosphates; Prodrugs; Thienamycins | 2009 |
1 other study(ies) available for micafungin and fosfluconazole
| Article | Year |
|---|---|
Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin.
We herein report the case of an 85-year-old woman presenting with right internal jugular vein candidal thrombophlebitis associated with central venous catheters (CTCVC). The infecting agent was Candida albicans, which caused recurrent candidemia five times in total. Micafungin (MCFG) alone was ineffective; however, the combination of MCFG with fosfluconazole (F-FLCZ) successfully treated the patient without a need for any anticoagulant or surgical therapies. To the extent of our knowledge, this is the first report of CTCVC being successfully treated with a combination of F-FLCZ and MCFG. These new antifungal agents have better efficacy, tolerability and bioavailability; therefore, they can be useful alternatives to classical combination therapies such as amphotericin-B and 5-fluorocytosine. Topics: Aged, 80 and over; Antifungal Agents; Candidemia; Catheter-Related Infections; Central Venous Catheters; Drug Therapy, Combination; Echinocandins; Female; Fluconazole; Humans; Jugular Veins; Lipopeptides; Micafungin; Organophosphates; Recurrence; Thrombophlebitis; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color | 2013 |